Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely aligns with the labeled information for Invokamet (canagliflozin/metformin). Most core claims about mechanism, combination product concept, dosing considerations, and key safety topics are supported by the provided label sections (notably 2.1, 2.3, 4, 5.x, 6, 12.x). A minority of claims are not fully supported or are only partially supported (notably some detailed dosing statements for IR/XR, certain miss-dose guidance, and specific adverse-effect listings), leading to some omissions and minor inconsistencies. Overall, the response is mostly aligned with labeling language but would benefit from more precise alignment to the exact wording and dosing guidance in the label.
Category Scores
Accurate Statements
Invokamet and Invokamet XR are fixed-dose two-drug tablets that combine canagliflozin (an SGLT2 inhibitor) with metformin (a biguanide).
2.1, 2.3
Invokamet is used in adults with type 2 diabetes when a dual therapy is needed to improve blood glucose control.
2.1
Invokamet can be used to add canagliflozin to metformin, or as the fixed-dose combination instead of taking two pills separately.
2.1
Canagliflozin helps the kidneys remove excess sugar through urine.
12.1
Metformin reduces liver glucose production.
12.2
Metformin improves insulin sensitivity.
12.2
Together, canagliflozin and metformin help lower blood sugar.
2.1
The exact strengths depend on the product (IR vs XR) and kidney function.
2.3
Invokamet XR dosing is prescribed by a clinician based on current therapy and kidney function.
2.3
The dose is chosen by your clinician based on your current therapy and kidney function.
2.3
Do not crush or chew the pills; swallow them whole unless your label says otherwise.
2.3
If you miss a dose, skip it and take the next one at your usual time (do not double up).
2.6
Common adverse effects include genital yeast infections.
6
Common adverse effects include urinary tract infections.
6
Metformin-related lactic acidosis is rare but serious.
4
Lactic acidosis risk with metformin is higher when kidney function is poor.
4
Lactic acidosis risk with metformin increases with dehydration.
4
Lactic acidosis risk with metformin increases when very ill.
4
Canagliflozin-related ketoacidosis is a rare risk, even with normal blood sugar.
5.1
There is a warning about foot/leg amputations from some canagliflozin data.
5.2
Hypoglycemia risk rises if Invokamet is used with insulin or other diabetes medications that can cause low blood sugar.
5.5
Invokamet is not for type 1 diabetes.
4
Invokamet is not for diabetic ketoacidosis.
4
Invokamet is not for severe kidney disease.
4
Invokamet is not recommended in pregnancy unless advised by your provider.
8.1
Invokamet IR and Invokamet XR have different strengths (strengths depend on product).
2.1
Unsupported Statements
Invokamet IR is commonly taken once daily with meals.
Not directly supported by labeled dosing instructions in the provided sections.
Common adverse effects include increased urination.
Not listed as an explicit separate adverse effect in the provided adverse reactions extract.
Common adverse effects include thirst.
Not listed as an explicit adverse effect in the provided adverse reactions extract.
Common adverse effects include nausea.
Not listed as an explicit adverse effect in the provided adverse reactions extract.
Common adverse effects include diarrhea.
Not listed as an explicit adverse effect in the provided adverse reactions extract.
Common adverse effects include upset stomach.
Not listed as an explicit adverse effect in the provided adverse reactions extract.
Contradictions
Important Omissions
Storage and handling specifics (beyond general instructions) are not provided in the claims.
Importance:
Moderate
Explicit contraindication language for hypersensitivity and boxed warning language is not enumerated in the findings.
Importance:
Moderate
Detailed administration phrasing beyond general 'do not crush' and 'missed dose' guidance (e.g., timing nuances for XR vs IR with meals) is not fully captured.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most statements align with labeling and cover key safety topics (DKA, amputation risk, hypoglycemia with insulin/secretagogues, genital infections). A few statements are not fully supported or are partially supported, which introduces some uncertainty but does not indicate a high safety risk based on the provided evidence.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Need fuller alignment on specific IR/XR dosing language, explicit adverse-effect phrasing, and complete administration/storage details.
Suggested Improvement
Map each claim to exact label language where possible (especially dosing for IR vs XR, missed-dose guidance, and specific adverse events). Include explicit contraindication language (hypersensitivity) and boxed warnings if applicable. Add precise storage/handling and monitoring recommendations as present in the label.